In July 2015, CIP VI was the lead investor in a transaction, committing $645m, which allowed Irving Place Capital to reposition its 2006-vintage fund and establish a new investment vehicle.
In September 2014, CIP VI acquired a €175m funds & directs portfolio from a leading Italian bank, Monte dei Paschi di Siena.
In May 2014, CIP VI was a leading member of an investor group which established American Capital’s third private equity fund, that consisted of seven companies from previous funds and capital for new investments.
In December 2013, CIP VI was part of a syndicate which purchased the interests of Absa Capital Private Equity Funds I from Barclays Africa Group.
In August 2012, CIP VI agreed to fund the acquisition of a $1.9bn private equity portfolio from Lloyds Banking Group.
In December 2011, CIP VI acquired 100% of Crédit Agricole Private Equity (CAPE) and the majority of the underlying funds that CAPE manages.
In July 2010, CIP VI, formed a joint venture with Lloyds Banking Group to acquire a £480m portfolio from the bank.
In September 2009, CIP V, purchased the majority of 3i’s remaining venture portfolio of technology and life sciences companies alongside HarbourVest Partners and DFJ Esprit. Coller Capital won Venture Capital Deal of the Year, 2009 for this transaction.
In February 2009, CIP V participated in an innovative rights issue and share placement by SVG Capital plc – the major investor in Permira buyout funds. Through this rights issue, CIP V acquired a 20% stake in the business.
In November 2008, the first commitment was made to a series of CLO porfolios across CIP V, CIP VI and CIP VII funds.
In March 2007, CIP V established a $1bn joint venture with Shell to develop a portfolio of 34 investments. The joint venture structure enables Shell to maintain its existing strategic links with the portfolio companies, whilst benefiting from Coller Capital’s expertise and resources as a financial investor.
In December 2006, CIP IV formed a €193m joint venture with ABN AMRO Capital. Forbion Capital Partners span out of the bank to manage the portfolio of 26 life science companies.
In January 2006, CIP IV invested in ICICI Venture's India Advantage Fund I - India's first secondaries transaction. Coller's proposals were tailored to meet the needs of individual sellers.
In September 2004, CIP IV acquired a $90 million portfolio of companies from Dresdner Kleinwort Benson.
In January 2004, CIP IV closed another landmark secondaries investment – the acquisition of a $900 million portfolio from Abbey bank (now part of Banco Santander). The deal involved 41 fund positions, 32 different managers, 16 direct investments, and around 850 underlying companies. The transaction was, at the time, the largest secondaries investment by a single firm.
In December 2001, CIP IV acquired the majority (and subsequently all) of Lucent’s corporate venture portfolio. The assets consisted of 27 companies based on technologies developed at the well-known Bell Labs in the late 1980s and the early 1990s.
In June 2000, CIP III led the acquisition of NatWest’s large private equity portfolio. The NatWest deal was notable for its unprecedented size and complexity – with a value in excess of $1 billion, it was the largest secondaries transaction of its time.
In June 1998, CIP III purchased the private equity funds portfolio of Shell’s US pension fund. Coller Capital's fund acquired the entire portfolio for $265 million. The transaction was a milestone for the private equity secondaries market – the largest secondaries deal of its time.